A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease

Kiora Pharmaceuticals

Status and phase: Terminated; Phase 2

Conditions: Dry Eye Disease

Treatments: Drug: KIO-101

Study type: Interventional

Funder types: Industry

Identifiers

NCT05629364

KIO-101-2201

Details and patient eligibility

About

A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, versus Vehicle Control in the treatment of Dry Eye Disease in Patients with Autoimmune Disease

Enrollment: 4 patients

Sex: All

Ages: 21+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have a diagnosis of autoimmune disease (psoriatic arthritis, Systemic Lupus Erythematosus (SLE), or fibromyalgia) ≤ 10 years
• Have an Ocular Discomfort Score (ODS) score of ≥3 at Screening
• Have an average VAS score ≥ 50 at Screening; and ≥ 40 at Baseline, Visit 2/Day 1
• Schirmer's 1 test >1 but < 10 mm at Screening.
• National Eye Institute (NEI) corneal fluorescein staining score of ≥ 4 at Screening (Day 14) provided that the total NEI score did not change > ± 2 grades from Screening (Day -14) to Baseline (Day 1) visits, as confirmed by the investigator
• Have a Best Spectacle Corrected Visual Accuity (BSCVA) score of 20/200 (+1.0 LogMAR) or better in both eyes at both the Screening and Baseline visits
• Have a conjunctival hyperaemia score of Grade 2 or more on the Efron Scale in both eyes

Exclusion criteria

• Have a history or presence of any ocular disorder or condition (other than dry eye disease (DED)) in either eye that would, in the opinion of the investigator, likely interfere with the interpretation of the study results or subject safety
• Have an autoimmune based vasculitis
• Have a history of RA > 10 years.
• Have a Schirmer's 1 test score of 0 to 1mm at Screening
• Have had a corneal transplant in either or both eyes
• Have had puncta or intracanalicular plug present in either eyelid within 1 year prior to the Screening Visit or anticipated plug insertion or occlusion at any time during the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Quadruple Blind

---

4 participants in 3 patient groups, including a placebo group

0.15% KIO-101

Experimental group

Description:

.15% KIO-101 eyedrops

Treatment:

Drug: KIO-101

0.3% KIO-101

Experimental group

Description:

0.3% KIO-101 eyedrops

Treatment:

Drug: KIO-101

Vehicle

Placebo Comparator group

Description:

Vehicle eyedrops

Treatment:

Drug: KIO-101